FWBI Company Profile and Key Details
First Wave BioPharma, Inc.
FWBI Stock Price Chart
Stock Price Today
First Wave BioPharma, Inc. (FWBI) stock surged +4.59%, trading at $2.96 on NASDAQ, up from the previous close of $2.83. The stock opened at $2.93, fluctuating between $2.84 and $3.04 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Company Information
| Employees | 9 |
| Beta | 1.28 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
First Wave BioPharma, Inc. (NASDAQ: FWBI) stock price is $2.96 in the last trading session. During the trading session, FWBI stock reached the peak price of $3.04 while $2.84 was the lowest point it dropped to. The percentage change in FWBI stock occurred in the recent session was 4.59% while the dollar amount for the price change in FWBI stock was $0.13.
The NASDAQ listed FWBI is part of Biotechnology industry that operates in the broader Healthcare sector. First Wave BioPharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Sarah Romano CPA
Chief Financial Officer
Mr. James R. Sapirstein M.B.A., R.Ph.
Pres, Chief Executive Officer & Chairman
Ms. Sarah Romano C.P.A.
Chief Financial Officer
Ms. Amy Chandler-Skerkis
Vice President of Regulatory Affairs, QA & Compliance
Mr. Martin Krusin M.B.A.
Senior Vice President of Corporation Devel.
Dr. James E. Pennington M.D.
Consultant
FWBI's closing price is 26.85% higher than its 52-week low of $2.33 where as its distance from 52-week high of $60.00 is -95.07%.
Number of FWBI employees currently stands at 9.
Official Website of FWBI is: https://www.firstwavebio.com
FWBI could be contacted at phone 561 589 7020 and can also be accessed through its website. FWBI operates from 777 Yamato Road, Boca Raton, FL 33431, United States.
FWBI stock volume for the day was 56.36K shares. The average number of FWBI shares traded daily for last 3 months was 72.48K.
The market value of FWBI currently stands at $5.99M with its latest stock price at $2.96 and 2.03M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com